Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Biomaterials|November 25, 2010
Hydrophilic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous cathetersKris N J Stevens, Sander Croes, Rinske S Boersma, et al.JTO Clinical and Research Reports|May 11, 2023
Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With OsimertinibAnita J W M Brouns, Ard van Veelen, G D Marijn Veerman, et al.Journal of Clinical Pharmacology|July 31, 2025
Osimertinib Cost Minimization in Non-Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination With CobicistatNiels Westra, Paul D Kruithof, Sander Croes, et al.Targeted Oncology|April 13, 2018
The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort StudyLotte M Knapen, Rutger H T Koornstra, Johanna H M Driessen, et al.Immunotherapy|June 9, 2023
Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial resultsMarjon V Verschueren, Talitha Dijs, Judith L Gulikers, et al.Diabetes, Obesity & Metabolism|November 25, 2016
Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort studyLotte M Knapen, Roy G P J de Jong, Johanna H M Driessen, et al.British Journal of Cancer|June 11, 2024
Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancerJudith L Gulikers, Leila-Sophie Otten, Lizza E L Hendriks, et al.Therapeutic Drug Monitoring|July 13, 2017
Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical ValidationLisa C Martial, Karin E J Hoogtanders, Michiel F Schreuder, et al.Biomedical Chromatography : BMC|March 20, 2023
Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasmaJudith L Gulikers, Ard J van Veelen, Elishia M J Sinkiewicz, et al.International Journal of Cancer|June 28, 2021
Toxicity of pemetrexed during renal impairment explained-Implications for safe treatmentRené J Boosman, Thomas P C Dorlo, Nikki de Rouw, et al.Pageof 5